ReviewPharmaceutics2021
Can the Nasal Cavity Help Tackle COVID-19?
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Trial
- Standardization of nasal airway structure model of Chinese Han nationality for characterization of nasal formulation spatial deposition atlases.Acta pharmaceutica Sinica. B · 2025Article
- Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta pharmaceutica Sinica. B · 2024Review
- Nasal sprays for treating COVID-19: a scientific note.Pharmacological reports : PR · 2023Review
- Recent advances in respiratory immunization: A focus on COVID-19 vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Lessons learned from COVID-19 pandemic: Vaccine platform is a key player.Process biochemistry (Barking, London, England) · 2023Article
- Prediction of transport, deposition, and resultant immune response of nasal spray vaccine droplets using a CFPD-HCD model in a 6-year-old upper airway geometry to potentially prevent COVID-19.Experimental and computational multiphase flow · 2023Article
- Advances in Development, Characterisation and Application of Nasal Drug Delivery Systems.Pharmaceutics · 2022Article
- An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).Cellular & molecular biology letters · 2022Review
- Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges.Immunity, inflammation and disease · 2022Review
- Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic.Pharmaceutics · 2022Review
- Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines.Pathogens (Basel, Switzerland) · 2022Review
- Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.Frontiers in immunology · 2022Article
- A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19.Frontiers in microbiology · 2022Review
- In vitro activity of cysteamine against SARS-CoV-2 variants.Molecular genetics and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the progress made in the fight against the COVID-19 pandemic, it still poses dramatic challenges for scientists around the world. Various approaches are applied, including repurposed medications and alternative routes for administration. Several vaccines have been approved, and many more are under clinical and preclinical investigation. This review aims to systemize the available information and to outline the key therapeutic strategies for COVID-19, based on the nasal route of administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.